A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy
Clinical trial NCT04590599 · COMPLETED
Trial details
- NCT number
- NCT04590599
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-08
- Primary completion
- 2023-11-20
- Enrollment
- 205
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.